LLPC geassocieerde studies

Open studies

Naam ZUMA-2 cohort 3
Titel A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2)
Status Open in AUMC (AMC), EMC & UMCG
Medicatie KTE-X19
Populatie r/r MCL BTKi-naive (i.e. Ibrutinib, Acalabrutinib)
Documenten Subject eligibility
Naam Lym1002

A Phase 1b, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Combination with JNJ-67856633 in Participants with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Status Open in AUMC
Medicatie BTK-inhibitor i.c.m. MALT-inhibitor
Populatie DLBCL (> 1ste lijn; ook post CAR-T); FL (> 2de lijn; ook getransformeerd/ 3B); CLL, MCL, MZL en WM (> 2 lijn), Eerdere behandeling met BTK-i toegestaan (tenzij progressie de reden van staken was).
Documenten In en exclusiecriteria
Titel A phase 1 and 2a open-label study to evaluate the safety, tolerability, pharmaco­kinetics, pharmacodynamics, immunogenicity and antitumor activity of LAVA-051 in patients with relapsed or refractory CD1d-positive chronic lymphocytic leukemia, multiple myeloma or acute myeloid leukemia
Status Open

Deelnemers Amsterdam UMC - AMC (A. Kater)
Amsterdam UMC - VUmc (N. van de Donk)
Erasmus MC (A. Broijl)

A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; 
DuoBody®-CD3xCD20) in Combination with Other Agents in Subjects with B-cell Non-Hodgkin Lymphoma 

Status Open

The study is open at Erasmus MC (;;; and UMCU (; The study will also open at: MUMC (; VUMC (, and LUMC (

Studie info

The study is temporarily closed for accrual

Documenten In en exclusiecriteria
Naam GEN3009

Safety and Efficacy of GEN3009 (DuoHexaBody®-CD37) in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma – A
First-in-Human, Open-label, Phase I/IIa Dose Escalation Trial with Dose Expansion Cohorts

Status Open
Deelnemers Open in VUMC (
Gaat ook open in Utrecht, Rotterdam  en Maastricht
Documenten In en exclusiecriteria


Short name TRANSCEND WORLD (Celgene JCAR017-BCM-001)
Studie title A phase 2, single-arm, multi-cohort, multicenter trial to determine the efficacy and safety of JCAR017 in adult subjects with aggressive B-Cell non-Hodgkin lymphoma.
Status Open
Deelnemers De studie is open in het Erasmus MC (;;
Studie info Open zijn nu cohort 4 (firstline therapy high grade B-cell lymphoma with MYC and BCL2 and / or BCL6 translocations) en cohort 5 (PCNSL who failed therapy with high dose chemotherapy and ASCT; no prior WBRT) Open is ook cohort 7, derdelijns poliklinische behandeling met CAR T-cells, voor zelfde indicatie als axi-cel

Aanvullende in- en exclusie criteria
Informeer eerst of er een slot beschikbaar is voor de verschillende cohorten!


Titel A phase 1-2, open-label, dose-escalation and expansion trial of GEN3013 (bispecific antibody CD20xCD3, epcoritamab) in patients with relapsed, progressive or refractory B-Cell lymphoma.
Status Open
Deelnemers The study is open at Erasmus MC (;;; VUMC (;, UMCU (; and MUMC (
Studie info The study is in the expansion phase. Patients with relapse or refractory FL grade 1-3a, MZL, SLL or mantle cell lymphoma may be included, after at least 2 prior lines of therapy. The study is closed for aggressive B-NHL.
Documenten In- en exclusie criteria


Naam EDO-S101-1001
Titel Phase 1 study to investigate the safety, pharmacokinetic profiles and efficacy of EDO-S101 (tinostamustine), a first-in-class alkylating histone deacetylase inhibition (HDACi) fusion molecule in relapsed/refractory hematological malignancies.
Status Open

The study is open at Erasmus MC (;; and VUMC (;
The study will also open at LUMC

Studie info

The study is in stage 2 = expansion phase and is open for:
Cohort 2: rr Hodgkin lymphoma after ≥ 2 prior lines therapy
Cohort 4: rr CTCL (MF; SS), ≥ 1 and ≤ 4 prior lines of systemic therapy

Documenten In- and exclusion criteria
Naam R/R CLL
Studie title Phase 1b/2 GEN3013 Monotherapy Study De
Studie drug Epcoritamab (subcutaneous CD3xCD20

Currently open in: Amsterdam UMC, AMC
Will be opened at: Universitair Medisch Centrum Groningen & Maastricht University Medical Center

Studie info R/R CLL after receiving at least 2 prior lines of systemic antineoplastic therapy, including treatment with (or intolerance of) a BTK inhibitor and with active CLL disease that needs treatment per iwCLL2018
Studie docs In- and exclusion criteria

Planned trials


Naam NP39461
Titel Open-label, dose escalation/expansion phase IB study to evaluate the safety, pharmacokinetics, and clinical activity of the combination of RO6870810 and venetoclax, with or without rituximab, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Status Gepland
Documenten Protocol synopsis
In- en exclusiecriteria


Gesloten Studies

Naam  CDK9
Title A Phase 1, Open-Label, Multicentre, Non-Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD4573, a Potent and Selective CDK9 Inhibitor, in Subjects with Relapsed or Refractory Haematological Malignancies.
Status Closed
Deelnemers De studie is open in het AMC en het Antonius Ziekenhuis Nieuwegein
Documenten Eligibility criteria
Naam ACT15320
Titel A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab in combination with other anti-cancer therapies in participants with lymphoma.
Status Closed
Deelnemers MUMC
Naam BELINDA (CCTL019H2301)
Titel Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial
Status Closed
Deelnemers AMC en UMCUtrecht
Documenten Flow en inclusie criteria
Naam TRANSFORM (Celgene JCAR017-BCM-003)
Titel A global randomized multicenter phase 3 trial to compare the efficacy and safety of JCAR017 (Car-T-cell) to standard of care (autologous SCT) in adult subjects with high-risk, transplant-eligible relapsed or refractory aggressive B-cell non-Hodgkin lymphomas
Status Closed
Deelnemers Erasmus MC (;;
Documenten In- en exclusie criteria


Naam Harbour
Studie title Phase 1b study with blinatumumab in combination with pembrolizumab treatment in 3th line DLBCL
Status Closed
Deelnemers The study is open at Erasmus MC (;;; MUMC ( and Radboudumc (
Studie info The study is on hold in the dose escalation phase. The dose expansion phase will probably start 01-01-2021
Studie docs In- and exclusion criteria